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SUMMARY ∑ The review covers the current practice of phototherapy with ultraviolet (UV) radia-
tion without sensitizers and of psoralen photochemotherapy (PUVA) in the treatment of psoriasis.
There are several types of UVB radiation in clinical use: traditional or broad band UVB (280 ∑ 320
nm); selective UVB (305 ∑ 325 nm); and narrow band UVB (311 nm). Forms of PUVA therapy are:
systemic photochemotherapy (PUVA therapy with oral administration of psoralen); PUVA bath
therapy; and PUVA therapy with topical psoralen application. PUVA therapy is more effective than
UVB therapy in clearing psoriasis in most patients, but since UVB is easier to administer and does
not involve an oral photosensitizing medication, it is often selected before PUVA. UVB and PUVA
have been administered alone or in combination with topical corticosteroids, salicylic acid, anthralin,
calcipotriol and tazarotene, and with systemic therapies such as retinoids. The most important po-
tential long-term side effects of UVB and PUVA are accelerated skin aging and an increased risk of
cutaneous cancer.
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Introduction
Since ancient times, the beneficial influence of sun-
light radiation on a broad variety of diseases has been rec-
ognized, and a variety of therapies based on these obser-
vations have been developed. The first artificial light
source, in the form of a carbon arc, was used for the treat-
ment of lupus vulgaris by Niels Finsen in 19031.
Early in the 20th century, so-called helio- or actino-
therapy for psoriasis enjoyed great popularity, especially
in Europe. In the beginning, phototherapy for psoriasis
was performed primarily by using broad spectrum ultra-
violet radiation. In 1923, Alderson started to use quartz-
jacketed mercury vapor lamps at erythemogenic doses to
improve psoriatic skin lesions; in 1925, Goeckerman
added crude coal tar to enhance the effects of ultraviolet
radiation. Since then, therapeutic regimens of psoriasis
have been amply modified, including both variation of
ultraviolet radiation spectra and combination of photo-
therapy with adjunctive agents2.
Phototherapy (UVB)
Phototherapy (UVB) is indicated for patients with
generalized plaque, guttate psoriasis, or palmoplantar pso-
riasis who have not responded adequately to conventional
topical therapies1. Since UVB is easier to administer and
does not involve an oral photosensitizing medication, this
form of phototherapy is often selected before psoralen
photochemotherapy (PUVA). In addition, factors that
suggest use of UVB therapy in comparison to PUVA
therapy are: brief history of psoriasis, as it is possible that
KostoviÊ K. et al Phototherapy (UVB) and Photochemotherapy (PUVA) for psoriasis
104 Acta clin Croat, Vol. 41, No. 2, 2002
maintenance treatment will be unnecessary (acute guttate
psoriasis); less than 30% of the body surface involved by
the disease before treatment; thin, macular psoriasis;
young age; and skin type I or II3.
There are several types of UVB radiation in clinical
use: 1) traditional or broad band UVB lamps deliver ra-
diation over 280 ∑ 320 nm; 2) selective UVB phototherapy
(SUP) has peaks at 305 and 325 nm; 3) narrow band UVB
lamps (Philips TL01) deliver almost exclusively 311 nm
radiation4.
Patients treated with narrow band UVB lamps (311
nm) showed faster clearing of psoriatic lesions, fewer epi-
sodes of excessive erythema, and longer period of remis-
sion when compared with broad band sources5-10. When
TL-01 phototherapy and PUVA were compared, there
was little overall difference in efficacy11-13.
Before therapy is started, the minimal erythema dose
(MED) should be determined. MED is the minimal
amount of energy required to produce a uniform clearly
demarcated erythema response, usually at 24 hours. MED
is determined by exposing small areas of normal skin to
increasing doses of ultraviolet radiation, preferably using
a dose series with geometric increments (for example,
successive doses increased by 40%)14. The initial dose may
vary and is usually 0.75 ∑ 0.9 MED15.
Another approach is to plan the starting dose for pho-
totherapy according to the patient’s skin type. Fitzpatrick
developed a concept of skin types to categorize more
quickly an individual’s response to sunlight16. The skin
type is based on the person’s reaction to 30 min mid-day
sunlight for the first time in the summer (Table 1).
The choice of the starting dose for UVB phototherapy
based on skin type assessment is more widely practised in
the U.K. than MED testing17. At our Department of
Dermatology and Venerology, we also use this method.
The minimal frequency of treatment is three times a
week (usually on Monday, Wednesday and Friday), al-
though four or five treatments per week (on each week
day) are preferable and result in a higher rate of success.
The twice weekly schedule is usually ineffective15,18,19. For
total clearing, usually defined as less  than 5% total body
surface involvement for patients who begin with at least
30% body coverage, an average of 25-30 treatments are
required in both three- and five-times weekly regimens,
but patients with very thick plaques may need more treat-
ments or a change in therapy1,15. When patients have
reached a plateau in their response, a  tapering mainte-
nance schedule begins, enabling them to gradually de-
crease the frequency of treatments before discontinuing
phototherapy. The remission induced by UVB photo-
therapy is temporary and its duration displays consider-
able individual variation. Stern et al. demonstrated that
postclearing UVB phototherapy, even at a modest aver-
age frequency of six treatments per month, significantly
and substantially increased the interval during which the
disease remained under excellent control20.
UVB and topical agents
Topical corticosteroids are frequently used in conjunc-
tion with UVB phototherapy, but there is no consensus
as to whether they enhance the therapeutic response to
UVB. Several studies failed to demonstrate any significant
difference either in the number of treatments needed to
obtain clearing, or in the duration of remission21-23. Al-
though they may accelerate an early response, the contin-
ued use of steroids does not increase the efficacy of pho-
Table 1. Skin type classification and corresponding UVB minimal erythema dose
Skin type Reaction to first MED (mJ/cm3) for UVB
sun exposure of 3 MED
I Always burn, never tan 20 ∑ 30
II Usually burn, tan less than average 25 ∑ 35
III Sometimes burn, tan about average 30 ∑ 35
IV Rarely burn, tan more than average 45 ∑ 60
V Brown-skinned persons 60 ∑ 100
VI Dark-skinned persons 100 ∑ 200
MED = minimal erythema dose
(adapted from Fitzpatrick TB. The validity and practicability of sunreactive skin types I through VI. Arch Dermatol
1988;125:869-71)
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totherapy and may result in a shorter duration of re-
sponse1,4.
Topical salicylic acid, which is often used in the treat-
ment of psoriasis, can decrease the effectiveness of pho-
totherapy by providing photoprotection24.
Calcipotriol and other vitamin D analogues have a
well documented effect in the treatment of psoriasis.
Many studies have shown that the addition of topical
calcipotriol can enhance the effect of UVB therapy25-29.
It is important to instruct patients to apply calcipotriol
after phototherapy. This precaution may keep the
calcipotriol ointment from impeding the transmission of
UV light, to prevent the destruction of calcipotriol by
UVA radiation, and to possibly minimize any discomfort
that could arise in a small number of patients if calci-
potriol ointment is applied just before phototherapy30.
The Ingram method uses UVB light (either broad band
or narrow band) followed by topical anthralin. With ei-
ther source, the healing is more rapid and the cumulative
UVB dose lower than with monotherapy7,31-33. Well
known side effects are skin irritation and considerable
cosmetic inconveniences such as staining of the skin and
clothes. The Goeckerman regimen (UVB + tar) is not
clearly superior to UVB monotherapy and has lost accep-
tance in recent years2,4.
Tazarotene, a third generation retinoid, can also en-
hance the effect of phototherapy. Several studies have
shown that tazarotene plus UVB phototherapy are supe-
rior to UVB monotherapy in terms of both efficacy
(greater reduction in plaque elevation, scaling and erythe-
ma) and rapidity of action34-36. Schiener et al. compared
narrow band UVB with either topical calcipotriol or topi-
cal tazarotene. The comparison revealed no significant
therapeutic difference between the two regimens37.
UVB and systemic agents
The treatment of psoriasis with acitretin in concert
with UVB is emerging as a viable clinical strategy. Com-
pared with either acitretin (25 ∑ 50 mg) or UV light
monotherapy alone, the combination regimen enhances
efficacy and limits treatment frequency, duration, and
cumulative doses. Moreover, patients whose psoriasis does
not clear with monotherapy will often achieve significant
clearing with the combination of acitretin and photo-
therapy6,38-40.
Combinations of phototherapy with methotrexate or
cyclosporin A are to be avoided, since both agents enhance
the probability of UV induced skin tumors2.
Side effects
The main short-term problem is erythema (sunburn
reaction). Slightly erythematogenic UVB doses are con-
sidered necessary to clear psoriasis effectively but severe
sunburn reactions should be avoided. Well known ocular
side effects of UVB include conjunctivitis and keratitis,
and therefore eye protective glasses should always be worn
by both the patient and the phototherapy technician15,18.
The most important potential long-term toxicities of
UVB phototherapy are accelerated skin aging and an in-
creased risk of cutaneous cancer. Photoaging, in contrast
to true chronologic aging, is defined as skin changes as the
result of repeated ultraviolet exposure rather than due to
passage of time alone. It is clinically characterized by
coarseness, wrinkling, laxity, increased fragility, mottled
pigmentation, telangiectases, and atrophic or fibrotic ar-
eas41.
UVB phototherapy adds to the cumulative lifetime
UVB exposure, which is an etiologic risk factor for skin
cancer. However, there was no significant increase in the
risk of squamous cell carcinoma or basal cell carcinoma
following long-term exposure to UVB according to the
patient data from the 16-center United States PUVA
study42. Long-term studies in Europe of extensively UVB-
treated patients with psoriasis, the majority with type II
skin, also failed to show an increased incidence of skin
cancer43,44. On the contrary, Stern et al. studied 59 skin
cancer patients with severe psoriasis treated with tar and/
or UVB, matching case controls to allow for a number of
confounding factors. For high exposure UVB (more than
300 treatments) and/or high tar exposure (more than 90
months of at least weekly use), the rate of cutaneous car-
cinoma was 4.7 times that of the non-high exposure
group45.
Although there are isolated case reports of melanoma
occurring in patients who received phototherapy, a clear
correlation has not been established15.
Photochemotherapy (PUVA)
Photochemotherapy (PUVA) is a therapeutic method
that uses psoralen and exposure to longwave ultraviolet A
radiation (320 ∑ 400 nm). Psoralens are tricyclic furo-
coumarins naturally occurring in certain plants, most of
them being also synthetically produced46. Psoralens can
be used systemically or topically or as bath therapy. Cur-
rently, 8-MOP (methoxsalen) is most commonly pre-
scribed, but 5-MOP (bergapten) is also used where avail-
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able. The synthetic furocoumarin, 4,5,8-trimethylpsoralen
(TMP) is used for bathwater-delivered PUVA mainly in
Scandinavia. 8-MOP and 5-MOP are available as oral
preparations, which contain either crystals, micronized
crystals or solubilized psoralens in a gel matrix. The liq-
uid preparation induces earlier, higher and more reproduc-
ible peak plasma levels than the crystalline preparations47.
Psoralen molecules intercalate between strands of
DNA, and when they are exposed to UVA, they form
adducts with the DNA and thus interfere with cell pro-
liferation48,49. Psoralens are metabolized in the liver and
their metabolites are excreted in urine 12-24 hours after
peroral administration50.
The action spectrum of UVA ranges from 320 nm to
380 nm, however, shorter wavelengths of 320-340 nm
have recently been shown to be efficient in PUVA
therapy51,52.
Practically all forms of psoriasis respond to PUVA,
although the management of erythrodermic or general-
ized pustular psoriasis is more difficult47,53. The factors
that suggest use of PUVA therapy in comparison with
UVB therapy are: long history of psoriasis, so that main-
tenance therapy is an almost certain requirement; more
than 30% of the body surface involved by the disease be-
fore the treatment; thick plaques; involvement of the
palms and soles; nail disease; failure to respond to UVB
phototherapy; very active, aggressive disease with marked
inflammatory component; and skin types III and IV3.
All patients should be evaluated for their suitability for
PUVA prior to commencement of treatment (Table 2).













Age less than 10 years1
Previous or current non-melanoma skin cancer
Previous exposure to arsenic or ionizing radiation





Age less than 16 years1
Cataracts2
Bullous pemphigoid
Previous or concomitant treatment with methotrexate
Significant hepatic dysfunction2
Previous internal malignancy
1A lower age limit may be acceptable where topical psoralen is used; 2Oral psoralen only.
(British Photodermatology Group. British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994;130:246-55)
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Forms of PUVA therapy
Systemic photochemotherapy (PUVA therapy with
oral administration of psoralen)
All patients require complete eye examination when
initiating oral PUVA therapy, because psoralens can form
photoproducts with lens proteins and their accumulation
results in cataracts49. Evaluation of liver function before
PUVA is advised, particularly in patients at risk of hepatic
disease.
The usual dose of psoralens is 0.6 ∑ 0.8 mg/kg of 8-me-
thoxypsoralen or 1.2 ∑ 1.4 mg/kg of 5-methoxypsoralen
given 2 h prior to the skin exposure to UVA radiation. The
newer capsules allow for exposure 1 h after ingestion4,47.
The choice of initial UVA dose is of paramount im-
portance. There are very high interindividual differences
in the phototoxic response. Individual phototoxic response
is assessed by determining minimal phototoxic dose
(MPD). MPD is a dose of UVA radiation which produces,
upon administration of appropriate psoralen doses, a
sharply demarcated erythema on the exposed area after 72
hours. In practice, MPD is determined by exposure of
small areas of the thigh region to increasing UVA doses
of 0.5 ∑ 5 J/cm2 for skin types I and II, and 1.5 ∑ 9 J/cm2
for skin types III and IV. The phototoxic erythema thresh-
old value is determined by erythema readings 72 to 96
hours later54.
Two therapeutic protocols of PUVA-treatment for
psoriasis were developed simultaneously. The European
PUVA Study (EPS) protocol includes MPD as initial
dose, followed by four exposures per week. The weekly
UVA dose increase is 0.5 to 2.0 J/cm2, depending on the
patient’s phototoxic and pigment response55. Dermatolo-
gists from the USA mostly use the United States Coop-
erative Clinical Trial (USCCT) protocol. The initial UVA
dose is determined according to the patient’s skin type.
PUVA therapy is performed 2-3 times per week, with a
0.5 ∑ 1.5 J/cm2 increase in the UVA radiation dose56.
Success rates reported by the USCCT and EPS are
essentially similar: 88% vs 88.8% treatment response bet-
ter than marked improvement. However, in the former
trial, the median number of exposures until clearing was
higher (25 vs 20) and therefore the duration of the clear-
ing phase was twice (12.7 vs 5.3 weeks) as long as in the
latter55,56.
Maintenance therapy is performed quite commonly
when the European regimen is used. It consists of four
weeks of twice-weekly treatments at the last UVA dose used
for clearing, followed by four once-weekly exposures47,49,57.
According to the recommendation of the British
Photodermatology Group, maintenance therapy follow-
ing routine clearance of psoriasis should be avoided in
order to minimize cumulative UVA exposure. Mainte-
nance PUVA should only be considered if there is a rapid
relapse of psoriasis following clearance or as part of a ro-
tational regimen of second-line treatments58.
PUVA bath therapy
PUVA bath therapy has been popular in Scandinavia
for many years, however, since recently it has attracted
interest worlwide. Patients are bathing for 20 min in 150
l of water containing 0.5 ∑ 1.0 ml/l of 8-methoxypsoralen
or trimethylpsoralen at 37 °C4. UVA radiation is given
immediately after the bath, as the desired phototoxic ef-
fect vanishes rapidly59,61.
The advantages of PUVA bath therapy include the
absence of gastrointestinal (nausea, vomiting), hepatic
(elevation of liver transaminases) and ocular side effects
because there is no systemic photosensitization61-63.
In three European studies, PUVA bath therapy has
shown greater efficacy than oral PUVA therapy62-64. The
same therapeutic effect required smaller cumulative UVA
doses and lower number of exposures.
PUVA therapy with topical psoralen application
The application of 8-MOP in creams, ointments or
lotions followed by UVA irradiation is efficacious in clear-
ing psoriasis but has several disadvantages. The non-uni-
form distribution on the skin surface induces unpredict-
able phototoxic erythema reactions and irregular patches
of cosmetically unacceptable hyperpigmentation65.
Combination treatments
Topical adjuvant therapies with corticosteroids, an-
thralin, and more recently with calcipotriol and
tazarotene have been tried with some success. Topical
application of corticosteroids reduces the time to remis-
sion, however, relapses occur sooner than without their
use66. The efficacy of PUVA therapy is increased by topi-
cal application of cignolin67. Two studies have shown
that phototherapy can be enhanced by the use of
calcipotriol. The first and the largest study of this kind
was performed in France and Belgium, and 103 patients
were involved68,69. The second study, performed the UK,
involved 13 patients only. In the PUVA bath study70, the
efficacy of tazarotene in combination with PUVA bath
therapy was evaluated in 12 patients with extensive
plaque psoriasis. The tazarotene plus PUVA bath therapy
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was clinically and statistically superior to the vehicle plus
PUVA bath therapy.
The combination of PUVA with systemic retinoids
(today we employ acitretin only, 30-50 mg) is one of the
most potent therapeutic regimens for psoriasis42. One
tends to employ retinoids first for 2-3 weeks. This flat-
tens lesions and reduces scale, facilitating PUVA therapy.
This combination, called RePUVA, has been reported to
reduce the number of exposures by one-third and the to-
tal cumulative UVA dose by more than one-half71.
RePUVA is used for ‘poor PUVA responders’, generalized
pustular psoriasis, and psoriatic erythroderma47,48.
The combination of PUVA and methotrexate during
the clearing phase reduces the duration of treatment,
number of exposures and total UVA dose, and is also ef-
ficacious in clearing patients unresponsive to PUVA or
UVB alone72.
In view of the possible long-term side effects (immu-
nosuppression, skin carcinogenesis), the combination of
PUVA plus cyclosporin A cannot be recommended73,74.
Side effects
Erythema is the most common acute side effect of
PUVA therapy. It is well known that erythema from
PUVA is delayed by 48 to 72 hours or longer in case of
severe reaction compared to that from UVB, which usu-
ally peaks within 12 hours. In two large studies, the inci-
dence of erythema accompanying PUVA therapy was
32.3% and 48%55,59. Mild pruritus is a very common com-
plaint. The most common cause of pruritus is dryness of
the skin and it responds to lubricants. PUVA therapy can
cause another type of pruritus, commonly called ‘PUVA
itch’, which is a deep, burning sensation75. It is a symp-
tom of phototoxicity. For extensive erythema and pruri-
tus, non-steroidal anti-inflammatory drugs and topical
corticosteroids may be required. Photo-onycholysis and
subungual hemorrhages are delayed signs of acute
phototoxicity in the nail bed47,76.
Oral administration of psoralens can induce systemic
side effects in the absence of light. Therapy with 8-MOP
is not infrequently disrupted by acute gastrointestinal
adverse reactions, mostly nausea and vomiting. In contrast,
5-MOP appears to be almost as efficacious as 8-MOP,
and is virtually free from these effects. However, 8% of
subjects are reported to develop an apparently harmless,
asymptomatic, maculopapular, intertriginous eruption
early during the treatment, which subsides spontaneously
despite continued treatment77. Hepatic adverse effects of
psoralens are uncommon, except perhaps in conjunction
with a pre-existing liver dysfunction78-80.
Careful pretreatment, ophthalmologic evaluation, and
eye protection during and after UVA exposure are neces-
sary to avoid acute inflammation of the conjunctiva and
cornea. Despite experimental data that indicated a risk of
premature cataract formation, prospective studies did not
find an increased frequency of cataracts in patients treated
with PUVA therapy81-84.
The major concern with prolonged and repeated
phototherapeutic regimens is the induction or promotion
of skin cancers. The risk factors for the development of
skin carcinoma following PUVA therapy include cumu-
lative dose of UVA radiation, skin type, previous treatment
for psoriasis (arsenic, UVB, methotrexate), and previous
skin alterations85. Almost all data were obtained from
psoriatics as they are the largest group of patients receiv-
ing PUVA.
In the past 12 years (1990-2001), several studies have
been published that support the earlier U.S. findings86-88,
that PUVA can act as a complete carcinogen in humans.
In 1990, Stern et al. reviewed the incidence of male geni-
tal tumors in their ongoing study, with a 12.3-year follow-
up in 892 men89. There was a strong dose-dependent in-
creased risk of genital tumors associated with PUVA and
UVB in separate. The risk of invasive squamous cell car-
cinoma (SCC) of the penis and scrotum was 95.7-fold
that in the general population. These findings were sup-
ported by Perkins et al. who, in a retrospective survey of
130 men with an average exposure of 1142 J/cm2 in 98
months, found that 4% had SCC (31-fold risk in the gen-
eral population) and three patients had genital tumors
(362-fold rate found in the general population)90. Another
highly relevant study was that of Brynzeel et al., who ex-
amined 260 patients after an average follow-up period of
8.6 years. Of these, 4.6% had SCC and the risk was 12-
fold that in the general population, independently of other
risk factors91. Lever and Farr examined 54 British patients
who had received high doses of UVA radiation (>2000 J/
cm2), after a mean of 11.2 years. The diagnosis of SCC
of the skin at the sites protected from natural ultraviolet
radiation was made in 19% of the patients92.
Stern et al. performed a prospective study in a cohort
of 1380 patients with psoriasis who were first treated with
PUVA in 1975 and 1976, and evaluated risk factors as-
sociated with the development of cutaneous SCC and
basal cells cancers (BCC). From 1975 through 1996, 237
(17.17%) patients developed 1422 cutaneous SCC. From
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1975 through 1997, 247 (23.70%) patients developed
1042 BCC.
Based on all studies, it can be concluded that high-
dose exposure to PUVA is associated with a persistent,
dose-related increase in the risk of SCC, even among
patients without substantial exposure to other carcinogens.
Exposure to PUVA has by far less effect on the risk of
BCC93.
Based on a recent study in 944 Swedish and Finnish
patients, bath PUVA with trioxsalen seems to bear no
relevant risk of carcinogenesis94. In addition, no associa-
tion between cutaneous cancer and 8-MOP bath PUVA
was found in 158 Finnish psoriatic patients95. These data
on long-term safety of bath PUVA are encouraging, how-
ever, there are other opinions as well. Shepard and
Panizzon conclude that all forms of PUVA therapy, irre-
spectively of the route of 8-MOP administration, contrib-
ute to a dose-dependent increase in the risk of non-mela-
noma skin cancer96.
Except for anecdotal reports, malignant melanoma has
not been observed in PUVA treated patients until recently,
and no increase in melanoma was found in a large num-
ber of studies reported so far. However, in 2001, Stern
reported on 26 invasive or in situ melanomas in 23 patients
from a cohort of 1380 patients enrolled in the PUVA fol-
low-up study (16-center study). Stern concluded that 15
years after the first exposure to PUVA, an increased risk
of melanoma was observed in the cohort of PUVA treated
patients, this risk being greater in patients exposed to high
doses of PUVA (more than 250 treatments) and appear-
ing to increase with time97.
Although this report needs to be confirmed by other
multicenter trials, it is alarming since the association be-
tween exposure to ultraviolet light and development of
melanoma has been well established in both humans and
experimental animals. Until this study is validated, it is
recommended that the guidelines for PUVA therapy be
rigorously followed and that the contraindications be ex-
tended to include history or family history of melanoma
and patients who have already received >200 treatments98.
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Saæetak
FOTOTERAPIJA (UVB) I FOTOKEMOTERAPIJA (PUVA) U LIJE»ENJU PSORIJAZE
K. KostoviÊ, M. ©itum i I. Nola
Ovaj pregledni Ëlanak obuhvaÊa suvremenu primjenu fototerapije s UV zraËenjem bez senzibilizatora i psoralensku
fotokemoterapiju (PUVA) u lijeËenju psorijaze. U kliniËkoj je primjeni nekoliko vrsta UVB zraËenja: klasiËno ili UVB zraËenje
πirokog spektra (280 ∑ 320 nm); selektivno UVB zraËenje (305 ∑ 325 nm); UVB zraËenje uskog spektra (311 nm). Oblici
PUVA terapije su: sistemska fotokemoterapija (PUVA terapija s peroralnim uzimanjem psoralena); lijeËenje PUVA kupkama
(PUVA bath); PUVA terapija s lokalnom primjenom psoralena. Iako je u veÊine bolesnika PUVA terapija uËinkovitija od UVB
terapije, UVB terapija se obiËno odabire prije PUVA terapije zbog lakπe primjene, kao i stoga πto ne ukljuËuje uzimanje oralnog
fotosenzibilizatora. UVB i PUVA rabe se samostalno ili u kombinaciji s lokalnom primjenom kortikosteroida, salicilnom
kiselinom, antralinom, kalcipotriolom, te sa sistemskom primjenom lijekova kao πto su retinoidi. NajznaËajniji potencijalni
dugoroËno πtetni uËinci UVB i PUVA terapije su ubrzano starenje koæe i poveÊani rizik od raka koæe.
KljuËne rijeËi: Psorijaza, lijeËenje; LijeËenje ultraljubiËastim zraËenjem, metode; Fotokemoterapija (PUVA) metoda, LijeËenje
ultraljubiËastim zraËenjem, πtetni uËinci
